India - English - Central Drugs Standard Control Organization

devi form. - amikacin - inj - 100/250;mg - v.

India - English - Central Drugs Standard Control Organization

devi form. - amikacin - inj - 500mg - v.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bioveta a.s., czech republic - natrii citras anhydricus, natrii acetas anhydricus, natrii propionas, kalii chloridum, natrii chloridum, kalii dihydrogenophosphas - oral powder - 1.36.4.68.2.98.1.92.3.28 g

United States - English - NLM (National Library of Medicine)

silver star brands - potassium sulfate (unii: 1k573lc5tv) (potassium cation - unii:295o53k152), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), sodium phosphate, dibasic (unii: gr686lba74) (phosphate ion - unii:nk08v8k8hr) - uses*: homeopathic remedy for relieving symptoms of bladder problems. *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. relieves burning sensation frequent urination & urgency.

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

European Union - English - EMA (European Medicines Agency)

csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - cardiovascular - intended for repair of pericardial structures and for use as a prosthesis for the surgical repair of soft tissue deficiencies, which include: defects of the abdominal and thoracis wall, hernias (including diaphragmatic, femoral, incisional, inguinal, lumbar, paracolostomy, scrotal, and umbilical) and intracardiac and great vessel repair.

Malta - English - Medicines Authority

alembic pharmaceuticals europe limited palazzo pietro stiges, 103, strait street, valletta vlt 1436, malta - celecoxib - hard capsule - celecoxib 100 mg - antiinflammatory and antirheumatic products

Malta - English - Medicines Authority

alembic pharmaceuticals europe limited palazzo pietro stiges, 103, strait street, valletta vlt 1436, malta - celecoxib - hard capsule - celecoxib 200 mg - antiinflammatory and antirheumatic products